Ritonavir News and Research

RSS
Ritonavir, also known as Norvir, is a type of medicine called a protease inhibitor (PI). PIs act by blocking protease, a protein that HIV needs to make more copies of itself. Ritonavir was approved by the FDA on March 1, 1996, for use with other antiretroviral agents in the treatment of HIV infection in adults and children 2 years of age or older. Ritonavir is now approved with other anti-HIV drugs in the treatment of HIV-1 infection in children in individuals over 1 month in age. Studies have shown that ritonavir works as a booster for some other PIs. Taking ritonavir makes it possible to take a lower dose of the other PIs. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Gilead Sciences gets marketing authorization from European Commission for Vitekta tablets

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Merck to present pharmacokinetic data on once-daily ISENTRESS at EACS

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Phase III EINSTEIN trial program: XARELTO reduces risk of DVT and PE

Scientists create polymer additives that enhance orally administered drugs to reach bloodstream

Scientists create polymer additives that enhance orally administered drugs to reach bloodstream

New polymer additives enhance ability of oral drugs to reach bloodstream

New polymer additives enhance ability of oral drugs to reach bloodstream

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Spectrum Pharmaceuticals enters into agreement to acquire Talon Therapeutics

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Bristol-Myers Squibb, Pfizer announce FDA acceptance of Eliquis sNDA for review

Key HIV drug prices continue to fall, but newer medicines still priced too high

Key HIV drug prices continue to fall, but newer medicines still priced too high

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

Study shows that PCCs can reverse blood thinning effects of XARELTO in healthy subjects

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

WHO's new HIV treatment guidelines call for immediate ART for HIV-infected children

Janssen receives complete response letter from FDA for XARELTO sNDA

Janssen receives complete response letter from FDA for XARELTO sNDA

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

GRACE study reports colored women are poorly represented in HIV drug trials

GRACE study reports colored women are poorly represented in HIV drug trials

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

FDA approves Arbor Pharmaceuticals' NDA for Nymalize oral solution

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Studies demonstrate encouraging results for new direct-acting antiviral agents

Studies demonstrate encouraging results for new direct-acting antiviral agents

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress